NL-OMON38582已完成不适用
A Phase I, Randomized, double-blind, placebo-controlled sequential study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ADX71441 after single oral ascending doses, and multiple oral ascending dose following a standard dose escalation schedule, randomized, double-blind for placebo and positive control, in normal healthy volunteers - Single and multiple ascending dose of ADX71441 in healthy male volunteers.
Addex Therapeutics SA0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Willing and able to provide written informed consent,
- •2. Male healthy volunteers 18 to 55 years of age,
- •3. Subjects with a weight of 75 ±15 kg at screening,
- •4. In good health as determined by medical history and physical examination,
- •5. Able to communicate well with the Investigator and research staff and willing and able to comply with all study procedures and visits,
- •6. Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the Principal Investigator (PI) and MM,
- •7. Negative test for selected drugs of abuse at the Screening visit,
- •8. Negative test for alcohol use (breathalyzer) at the Screening visit.
排除标准
- •1. Who has a positive hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]), or a positive HIV antibody screen,
- •2. Who previously received ADX71441,
- •3. Who present with acute or chronic or history of symptoms of gastrointestinal disturbances (GI) or on physical examination have evidence of any clinical signs of acute or chronic GI abnormality (i.e. hemorrhoids, GI bleeding, etc.),
- •4. Who have a history of chronic uncontrolled medical conditions that may cause a medical emergency in the case of a provoked seizure,
- •5. Who presents with any clinical abnormality identified during pre-study laboratory tests, full physical examination, vital signs, and ECG, unless deemed acceptable by the PI and the Sponsor,
- •6. Who present with a diagnosis of epilepsy or history of seizures or fainting spells of unknown or undetermined etiology or has a family history of treatment resistant epilepsy,
- •7. Who present with or have a history of progressive neurological disorder or focal signs of abnormality on neurological examination,
- •8. With any history of abnormal EEG or EEG signal suggesting a possible risk of epilepsy, febrile convulsions, etc.,
- •9. Who present with a history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV_TR,
- •10. Who have a history of moderate to severe depression, or suicide ideation,
- •11. Who have a history of allergy, intolerance or photosensitivity to any drug, or who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,
- •12. Who have a current or recent history (within 6 months of screening) of drug or substance abuse, including alcohol (>= 14 units per week), or who have a significant history of alcoholism or drug/chemical abuse within 6 months prior to the Screening visit (one unit of alcohol equals * pint [285 mL] of beer or lager, one glass [125 mL] of wine, or one shot [25 mL] of spirits),
- •13. Who drink more than 8 cups daily of beverage containing caffeine,
- •14. Who currently smoke or have used tobacco products (or equivalent) within 2 weeks prior to the screening visit,
- •15. Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,
- •16. Who currently use any prescription medications/products (with the exception of prescription medications deemed acceptable by the Investigator and Sponsor),
- •17. Use of any over the counter (OTC), non-prescription preparations (including vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations) within 14 days prior to the Check-in visit, unless deemed acceptable by the Investigator and Sponsor,
- •18. Who have any clinical condition or prior therapy which, in the opinion of the Investigator, make the subject unsuitable for the study , could compromise subject safety, limit the subject*s ability to complete the study, and/or compromise the objectives of the study,
- •19. Who have participated to any clinical trial with an investigational drug in the past 3 months preceding study entry,
- •20. Who have a history of a clinically significant cardiac disease (e.g., myocardial infarction or stroke within 6 months prior to Screening unstable angina, claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG) abnormality at Screening,
- •21. Who have a history of orthostatic hypotension or evidence orthostatic hypotension at Screening,
研究者
相似试验
进行中（未招募）
1 期
Single Ascending-dose Study of Injectable Favipiravirsevere fever with thrombocytopenia syndromeJPRN-jRCT2071210042Sakurai Tsutomu50
招募中
1 期
A Phase I Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers under Single Ascending Dose and Multiple Ascending Dose conditions.CTRI/2022/08/045056Godavari Biorefineries Ltd
进行中（未招募）
1 期
Multiple-dose Study of Injectable Favipiravirsevere fever with thrombocytopenia syndromeJPRN-jRCT2071210126Sakurai Tsutomu24
招募中
1 期
A Phase I, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of XG2002 Oral Administration in Healthy Adult VolunteersAcute and Chronic PainNeurological - Other neurological disordersACTRN12624000245594Xgene Pharmaceutical Pty Ltd32
已完成
1 期
A study to evaluate the safety, tolerability, processing by the body, and response of the body to the drug VK2735 in healthy adultson-alcoholic steatohepatitis (NASH)Digestive SystemOther specified inflammatory liver diseasesISRCTN47896018Viking Therapeutics, Inc.88